Zealand Pharma Stock Tumbles After Petrelintide Phase II Falls Short of Expectations
Shares of the Danish biotech slid as much as 30% after Phase II results for obesity candidate petrelintide reported weight loss of 10.7% at week 42 on the efficacy estimand for the highest dose, below many analysts' expectations. Analysts acknowledged a favorable tolerability profile and potential for improved outcomes in Phase III, but said curren…